The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis

Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis

(2010) James P. Brodeur et al.   ARTHRITIS AND RHEUMATISM

Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease‐modifying antirheumatic drug treatment and correlation with radiologic outcome

(2008) David Haynes et al.   ARTHRITIS AND RHEUMATISM

The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation

(2008) Bernard Vandooren et al.   ARTHRITIS AND RHEUMATISM

Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin

(2008) Giorgio Zauli et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway

(2008) Estelle Chamoux et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Conjunctival sac fluid contains elevated levels of soluble TRAIL: Implications for the anti-tumoral surveillance of the anterior surface of the eye

(2008) Paola Secchiero et al.   JOURNAL OF CELLULAR PHYSIOLOGY

sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis

(2008) Gert E. Hein et al.   RHEUMATOLOGY INTERNATIONAL

Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor‐kappa B ligand, and high‐sensitivity C‐reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate

(2008) H. P. Sennels et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY